These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38040995)

  • 1. Association Study Between Kynurenine 3-Monooxygenase (KMO) Gene and Parkinson's Disease Patients.
    Babu HWS; Elangovan A; Iyer M; Kirola L; Muthusamy S; Jeeth P; Muthukumar S; Vanlalpeka H; Gopalakrishnan AV; Kadhirvel S; Kumar NS; Vellingiri B
    Mol Neurobiol; 2024 Jul; 61(7):3867-3881. PubMed ID: 38040995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic variants of the kynurenine-3-monooxygenase and postpartum depressive symptoms after cesarean section in Chinese women.
    Wang SY; Duan KM; Tan XF; Yin JY; Mao XY; Zheng W; Wang CY; Yang M; Peng C; Zhou HH; Liu ZQ
    J Affect Disord; 2017 Jun; 215():94-101. PubMed ID: 28319697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kynurenine pathway in Parkinson's disease-An update.
    Venkatesan D; Iyer M; Narayanasamy A; Siva K; Vellingiri B
    eNeurologicalSci; 2020 Dec; 21():100270. PubMed ID: 33134567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls.
    Holtze M; Saetre P; Engberg G; Schwieler L; Werge T; Andreassen OA; Hall H; Terenius L; Agartz I; Jönsson EG; Schalling M; Erhardt S
    J Psychiatry Neurosci; 2012 Jan; 37(1):53-7. PubMed ID: 21693093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
    Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Hajibeygi R; Shool S; Sodeifian F; Klegeris A; McElhinney A; Tavirani MR; Sayehmiri F
    Front Immunol; 2022; 13():997240. PubMed ID: 36263032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiency of kynurenine 3-monooxygenase exacerbates impairment of prepulse inhibition induced by phencyclidine.
    Kubota H; Kunisawa K; Niijima M; Hirakawa M; Mori Y; Hasegawa M; Fujigaki S; Fujigaki H; Yamamoto Y; Saito K; Nabeshima T; Mouri A
    Biochem Biophys Res Commun; 2022 Nov; 629():142-151. PubMed ID: 36116377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral kynurenine-3-monooxygenase deficiency as a potential risk factor for metabolic syndrome in schizophrenia patients.
    Oxenkrug G; van der Hart M; Roeser J; Summergrad P
    Integr Clin Med; 2017; 1(1):. PubMed ID: 28748226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.
    Wonodi I; Stine OC; Sathyasaikumar KV; Roberts RC; Mitchell BD; Hong LE; Kajii Y; Thaker GK; Schwarcz R
    Arch Gen Psychiatry; 2011 Jul; 68(7):665-74. PubMed ID: 21727251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Footprint of Kynurenine Pathway in Neurodegeneration: Janus-Faced Role in Parkinson's Disorder and Therapeutic Implications.
    Behl T; Kaur I; Sehgal A; Singh S; Bhatia S; Al-Harrasi A; Zengin G; Bumbu AG; Andronie-Cioara FL; Nechifor AC; Gitea D; Bungau AF; Toma MM; Bungau SG
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
    Tashiro T; Murakami Y; Mouri A; Imamura Y; Nabeshima T; Yamamoto Y; Saito K
    Behav Brain Res; 2017 Jan; 317():279-285. PubMed ID: 27693848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.
    Wonodi I; McMahon RP; Krishna N; Mitchell BD; Liu J; Glassman M; Hong LE; Gold JM
    Schizophr Res; 2014 Dec; 160(1-3):80-7. PubMed ID: 25464917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
    Birner A; Platzer M; Bengesser SA; Dalkner N; Fellendorf FT; Queissner R; Pilz R; Rauch P; Maget A; Hamm C; Herzog-Eberhard S; Mangge H; Fuchs D; Moll N; Zelzer S; Schütze G; Schwarz M; Reininghaus B; Kapfhammer HP; Reininghaus EZ
    PLoS One; 2017; 12(2):e0172699. PubMed ID: 28241062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population.
    Aoyama N; Takahashi N; Saito S; Maeno N; Ishihara R; Ji X; Miura H; Ikeda M; Suzuki T; Kitajima T; Yamanouchi Y; Kinoshita Y; Yoshida K; Iwata N; Inada T; Ozaki N
    Genes Brain Behav; 2006 Jun; 5(4):364-8. PubMed ID: 16716206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo.
    Amori L; Guidetti P; Pellicciari R; Kajii Y; Schwarcz R
    J Neurochem; 2009 Apr; 109(2):316-25. PubMed ID: 19226371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
    Lavebratt C; Olsson S; Backlund L; Frisén L; Sellgren C; Priebe L; Nikamo P; Träskman-Bendz L; Cichon S; Vawter MP; Osby U; Engberg G; Landén M; Erhardt S; Schalling M
    Mol Psychiatry; 2014 Mar; 19(3):334-41. PubMed ID: 23459468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
    Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
    J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
    Johansson AS; Owe-Larsson B; Asp L; Kocki T; Adler M; Hetta J; Gardner R; Lundkvist GB; Urbanska EM; Karlsson H
    J Psychiatr Res; 2013 Nov; 47(11):1815-23. PubMed ID: 24012176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drosophila eye color mutants as therapeutic tools for Huntington disease.
    Green EW; Campesan S; Breda C; Sathyasaikumar KV; Muchowski PJ; Schwarcz R; Kyriacou CP; Giorgini F
    Fly (Austin); 2012; 6(2):117-20. PubMed ID: 22634544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.